| Literature DB >> 17439973 |
Buyong Ma1, Yongping Pan, Jie Zheng, Arnold J Levine, Ruth Nussinov.
Abstract
The p53 tetramer recognizes specifically a 20-bp DNA element. Here, we examined symmetries encoded in p53 response elements (p53REs). We analyzed base inversion correlations within the half-site, as well as in the full-site palindrome. We found that p53REs are not only direct repeats of half-sites; rather, two p53 half-sites couple to form a higher order 20 bp palindrome. The palindrome couplings between the half-sites are stronger for the human than for the mouse genome. The full-site palindrome and half-site palindrome are controlled by insertions between the two half-sites. The most notable feature is that the full-site palindrome with coupling between quarter-sites one and four (H14 coupling) dominates the p53REs without insertions. The most frequently observed insertion in human p53REs of 3 bp enhances the half-site palindrome. The statistical frequencies of the coupling between the half-sites in the human genome correlate with grouped experimental p53 affinities with p53REs. Examination of known p53REs indicates the H14 couplings are stronger for positive regulation than for negatively regulated p53REs, with repressors having the lowest H14 couplings. We propose that the palindromic sequence couplings may encode such potential preferred multiple binding modes of the p53 tetramer to DNA.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17439973 PMCID: PMC1888811 DOI: 10.1093/nar/gkm192
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 16.971
Counts of bases appearing in the experimentally verified p53 response elements (sequences are listed in the Appendix)
| Position | A | T | C | G |
|---|---|---|---|---|
| 1 | 31 | 10 | 7 | 52 |
| 2 | 28 | 4 | 11 | 57 |
| 3 | 37 | 10 | 14 | 39 |
| 4 | 1 | 3 | 95 | 1 |
| 5 | 55 | 31 | 11 | 3 |
| 6 | 32 | 56 | 2 | 10 |
| 7 | 3 | 0 | 1 | 96 |
| 8 | 7 | 33 | 48 | 12 |
| 9 | 6 | 19 | 69 | 6 |
| 10 | 6 | 37 | 45 | 12 |
| 11 | 27 | 8 | 17 | 48 |
| 12 | 28 | 2 | 8 | 62 |
| 13 | 36 | 3 | 13 | 48 |
| 14 | 1 | 5 | 90 | 4 |
| 15 | 48 | 33 | 12 | 7 |
| 16 | 30 | 55 | 6 | 9 |
| 17 | 4 | 2 | 2 | 92 |
| 18 | 6 | 47 | 41 | 6 |
| 19 | 5 | 32 | 52 | 11 |
| 20 | 5 | 42 | 39 | 14 |
There are total 100 sequences listed in Appendix. Thus the counts in this table are equivalent to percentage. The number of insertion of spacers: Zero spacer: 55; one spacer: 8; two spacers: 8; three spacers: 7; four spacers; 3; five spacers: 3; six spacers: 5; eight spacers: 5; 10 spacers: 3; 11 spacers: 1; 13 spacers: 1; 14 spacers: 1.
Figure 1.Definition of symmetric couplings. (a) Q-coupling is defined by the number of inverted bases between Q1 and Q2, and between Q3 and Q4 at each palindrome position in the half-sites. H-coupling measures the number of inverted bases between two half-sites at corresponding palindrome positions. (b) T-coupling describes how many bases are the same in respective positions in the two half-sites. (c) Overlap of three couplings occurs as long as any two of the Q-, H- or T-couplings overlap. The counts of overlapped couplings are removed from the statistics of the contributions of various coupling.
Fraction of bases involved in only H-coupling across the half-sites for all potential human p53REs
| Position | Consensus | A | T | C | G | Sum |
|---|---|---|---|---|---|---|
| 1 | 0.016 | 0.008 | 0.270 | |||
| 2 | 0.005 | 0.002 | 0.319 | |||
| 3 | 0.007 | 0.006 | 0.297 | |||
| 4 | 0 | 0 | 0 | 0.003 | ||
| 5 | 0.000 | 0 | 0.344 | |||
| 6 | 0 | 0 | 0.339 | |||
| 7 | 0 | 0 | 0 | 0.003 | ||
| 8 | 0 | 0.007 | 0.303 | |||
| 9 | 0.006 | 0.003 | 0.271 | |||
| 10 | 0.017 | 0.007 | 0.232 | |||
| 11 | 0.017 | 0.007 | 0.232 | |||
| 12 | 0.006 | 0.003 | 0.271 | |||
| 13 | 0 | 0.007 | 0.302 | |||
| 14 | 0 | 0 | 0.003 | 0 | 0.003 | |
| 15 | 0 | 0 | 0.339 | |||
| 16 | 0 | 0.000 | 0.344 | |||
| 17 | 0 | 0 | 0 | 0.003 | ||
| 18 | 0.007 | 0.006 | 0.297 | |||
| 19 | 0.005 | 0.002 | 0.319 | |||
| 20 | 0.016 | 0.008 | 0.271 |
Bold fonts are for consensus bases.
Fraction of bases involved in various couplings for potential human p53REs without a spacer (insertion) between the two half-sites
| H-coupling only | T-coupling only | Q-coupling only | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | Con | A | T | C | G | A | T | C | G | A | T | C | G | |
| 1 | 0.245 | 0.006 | 0.005 | 0.068 | 0.086 | 0.012 | 0.009 | 0.178 | 0.104 | 0.009 | 0.006 | 0.066 | ||
| 2 | 0.095 | 0.004 | 0.003 | 0.492 | 0.090 | 0.005 | 0.001 | 0.096 | 0.097 | 0.006 | 0.004 | 0.086 | ||
| 3 | 0.089 | 0.004 | 0.004 | 0.458 | 0.079 | 0.000 | 0.013 | 0.199 | 0.074 | 0.003 | 0.004 | 0.203 | ||
| 4 | 0.000 | 0.000 | 0.002 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.002 | 0.000 | ||
| 5 | 0.148 | 0.062 | 0.000 | 0.000 | 0.130 | 0.094 | 0.001 | 0.000 | 0.128 | 0.067 | 0.000 | 0.000 | ||
| 6 | 0.097 | 0.130 | 0.000 | 0.000 | 0.088 | 0.165 | 0.000 | 0.000 | 0.067 | 0.128 | 0.000 | 0.000 | ||
| 7 | 0.000 | 0.000 | 0.000 | 0.001 | 0.000 | 0.000 | 0.000 | 0.003 | 0.000 | 0.000 | 0.000 | 0.002 | ||
| 8 | 0.000 | 0.077 | 0.097 | 0.004 | 0.003 | 0.087 | 0.213 | 0.010 | 0.003 | 0.074 | 0.203 | 0.004 | ||
| 9 | 0.006 | 0.085 | 0.091 | 0.004 | 0.007 | 0.092 | 0.080 | 0.004 | 0.006 | 0.097 | 0.086 | 0.004 | ||
| 10 | 0.007 | 0.043 | 0.018 | 0.008 | 0.013 | 0.098 | 0.223 | 0.006 | 0.009 | 0.104 | 0.066 | 0.006 | ||
| 11 | 0.043 | 0.007 | 0.008 | 0.018 | 0.086 | 0.012 | 0.009 | 0.178 | 0.099 | 0.010 | 0.007 | 0.069 | ||
| 12 | 0.085 | 0.006 | 0.004 | 0.091 | 0.090 | 0.005 | 0.001 | 0.096 | 0.087 | 0.004 | 0.001 | 0.080 | ||
| 13 | 0.077 | 0.000 | 0.004 | 0.097 | 0.079 | 0.000 | 0.013 | 0.199 | 0.087 | 0.000 | 0.003 | 0.186 | ||
| 14 | 0.000 | 0.000 | 0.001 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.001 | 0.000 | ||
| 15 | 0.130 | 0.097 | 0.000 | 0.000 | 0.130 | 0.094 | 0.001 | 0.000 | 0.114 | 0.055 | 0.000 | 0.000 | ||
| 16 | 0.062 | 0.148 | 0.000 | 0.000 | 0.088 | 0.165 | 0.000 | 0.000 | 0.055 | 0.114 | 0.000 | 0.000 | ||
| 17 | 0.000 | 0.000 | 0.000 | 0.002 | 0.000 | 0.000 | 0.000 | 0.003 | 0.000 | 0.000 | 0.000 | 0.001 | ||
| 18 | 0.004 | 0.089 | 0.458 | 0.004 | 0.003 | 0.087 | 0.213 | 0.010 | 0.000 | 0.087 | 0.186 | 0.003 | ||
| 19 | 0.004 | 0.095 | 0.492 | 0.003 | 0.007 | 0.092 | 0.080 | 0.004 | 0.004 | 0.087 | 0.080 | 0.001 | ||
| 20 | 0.006 | 0.245 | 0.068 | 0.005 | 0.013 | 0.098 | 0.223 | 0.006 | 0.010 | 0.099 | 0.069 | 0.007 | ||
Figure 2.Sequence logos for three datasets. (a) Native p53REs (compiled in Appendix). (b) Artificial p53REs with strict consensus distributions in artificial dataset 1. (c) Artificial p53REs dataset 2 with overall base distributions identical to the dataset of native p53REs.
Figure 3.Frequencies of occurrence of the three couplings in potential p53REs in the human genome (a); the relative abundance of full-site palindrome over half-site palindrome in the potential human p53REs (b), mouse p53REs (c) and in a compiled dataset of known p53REs (d).
Figure 4.The relative abundance of degeneracy of the whole site over the half-site palindrome for human p53REs (a) and for mouse p53REs (b). Similarly, the relative abundance of degeneracy of two half-sites over full site palindrome for human p53REs (c) and for mouse p53REs (d) is also compared.
Figure 5.(a) Frequencies of occurrence of the three couplings in artificial p53REs; (b) the relative abundance of full-site palindrome over half-site palindrome in the random artificial p53REs. The artificial p53REs satisfy the consensus rule of p53RE however, there is no pattern for the difference between Q-coupling within the half-sites and H-coupling across half-sites.
Figure 6.Changes in the relative abundance of the full-site palindrome over the half-site palindrome for human p53REs (a) and for mouse p53REs (b) with several key insertions are highlighted. (c) Distributions of various insertions in human and mouse p53REs.
Figure 7.Frequencies of various combinations of consensus A/T bases in the WW region (5, 6, 15 and 16) are related to the number of insertions in human p53REs (a) and in mouse p53REs (b). The most notable feature is the AT × AT combination for the p53REs without insertion. Here, ∼80% of the AT × AT group combination with insertion have full-site palindrome, while <10% have quarter-site palindrome counts (c).
Five p53REs and proposed p53 coupling modes examined by an empirical weighting matrix
| Gene | Sequence | Q1234 | T13 | T24 | H14 | H23 | |
|---|---|---|---|---|---|---|---|
| p21-5′ | CTATGAG | Sum of fraction | 0.657 | 0.786 | 0.912 | 0.742 | 0.618 |
| Population% | 17.69 | 21.16 | 24.54 | 19.96 | 16.64 | ||
| Gad45A | TGTACA | Sum of fraction | 0.821 | 0.983 | 0.912 | 1.110 | 0.698 |
| Population% | 18.15 | 21.73 | 20.14 | 24.55 | 15.43 | ||
| pDINP1 | TTTATA | Sum of fraction | 0.597 | 0.919 | 0.633 | 0.896 | 0.457 |
| Population% | 17.04 | 26.24 | 18.08 | 25.58 | 13.05 | ||
| p53Aip | TCCTCC | Sum of fraction | 0.624 | 0.674 | 1.024 | 0.814 | 0.642 |
| Population% | 16.52 | 17.83 | 27.11 | 21.54 | 17.0 | ||
| Puma-BS2 | TGCCGC | Sum of fraction | 0.599 | 0.930 | 0.660 | 1.416 | 0.559 |
| Population% | 14.38 | 22.33 | 15.86 | 34.00 | 13.42 |
Comparison of computational quarter-site coupling probability and experimental p53–DNA affinity
| Group | P53REs | Q1234 | T13 | T24 | H14 | H23 | |
|---|---|---|---|---|---|---|---|
| Very strong binding | 14-3-3 σ s1 | 13 | 13.4 | 20.8 | 44.7 | 8.1 | 9.9 ± 2.1 |
| 14-3-3 σ s2 | 16.1 | 16.7 | 23.6 | 30.5 | 13.1 | 10 ± 2.1 | |
| GADD45 | 18.1 | 21.7 | 20.1 | 24.5 | 15.4 | 7.7 ± 1.2 | |
| Maspin | 18.9 | 18.4 | 22.2 | 22.4 | 18.1 | 9.2 ± 1.7 | |
| MDM2 | 13.7 | 21.8 | 16.5 | 33.6 | 14.4 | 12.3 ± 2.9 | |
| NOXA | 16.3 | 18.8 | 19.9 | 31.3 | 13.8 | 8.6 ± 1.6 | |
| P21-5′ site | 17.7 | 21.2 | 24.5 | 20 | 16.6 | 4.9 ± 0.6 | |
| P21-3′ site | 16.3 | 24.3 | 15.8 | 30.9 | 12.8 | 12 ± 7.0 | |
| P53AIP1 | 16.5 | 17.8 | 27.1 | 21.5 | 17 | 11.0 ± 1.8 | |
| P53R2 | 15.9 | 16 | 21.6 | 33.1 | 13.5 | 5.7 ± 0.8 | |
| PCNA | 17.1 | 26.2 | 20.2 | 21.5 | 15.1 | 6.6 ± 1.4 | |
| PIDD | 19 | 17.2 | 23.9 | 19.8 | 20.1 | 14.7 ± 5.0 | |
| PUMA-BS2 | 14.4 | 14.7 | 24.5 | 33.3 | 13.1 | 7.1 ± 1.8 | |
| Cyclin G | 14.5 | 15.4 | 20.8 | 37.3 | 12 | 7.8 ± 1.6 | |
| Group average | 16.3 | 18.8 | 21.6 | 28.9 | 14.5 | 9.1 | |
| Strong binding | KAI 1 | 18.9 | 19 | 22 | 24.7 | 15.4 | 33 ± 10.9 |
| Group average | 18.9 | 19 | 22 | 24.7 | 15.4 | 33 ± 10.9 | |
| Weak binding | Bax | 18.9 | 18.1 | 22.1 | 19 | 21.8 | 73 ± 33 |
| IGF-BP3 box A | 18.6 | 18.8 | 21.8 | 23 | 17.7 | 81 ± 25 | |
| P53DINP1 | 17 | 26.2 | 18.1 | 25.6 | 13 | 98 ± 23 | |
| Group average | 18.2 | 21 | 20.7 | 22.5 | 17.5 | 84 | |
| Very weak binding | P2XM | 18.7 | 21.3 | 19 | 24.3 | 16.7 | 221 ± 41 |
| PUMA-BS1 | 18.2 | 15.9 | 26.4 | 12.6 | 26.9 | 260 ± 50 | |
| Group average | 18.5 | 18.6 | 22.7 | 18.5 | 21.8 | 241 |
a Reference (13).
Figure 8.Correlation of five quarter-sites coupling modes with p53-binding affinity shows that the correlation between the H14 mode (correlation between quarter-sites one and four) favors p53 binding while the H23 mode (correlation between quarter-site two and three) interferes and decrease binding affinity.
Quarter-site coupling mode change for human and mouse p53RE with various spacers
| Number of spacer | Q1234 | T13 | T24 | H14 | H23 | Correlation ( | |
|---|---|---|---|---|---|---|---|
| 0 | |||||||
| 1 | 18.68 | 18.32 | 22.77 | 19.93 | 20.30 | 0.000 | |
| 20.91 | 20.84 | 20.67 | 16.9 | 20.68 | |||
| 2 | 18.54 | 18.58 | 21.77 | 20.35 | 20.75 | 0.5725 | |
| 18.39 | 19.93 | 22.20 | 20.03 | 19.45 | |||
| 3 | |||||||
| 4 | 17.94 | 19.77 | 22.52 | 20.92 | 18.86 | 0.3468 | |
| 13.90 | 14.10 | 15.84 | |||||
| 5 | 18.8 | 19.58 | 22.23 | 19.68 | 19.71 | 0.7523 | |
| 18.26 | 19.87 | 21.72 | 19.39 | 20.76 | |||
| 6 | 17.96 | 18.47 | 23.49 | 20.04 | 20.03 | 0.0142 | |
| 19.94 | 21.40 | 20.95 | 19.13 | 18.60 | |||
| 7 | 19.28 | 18.83 | 21.30 | 18.23 | |||
| 19.03 | 20.67 | 20.75 | 20.01 | 19.54 | |||
| 8 | |||||||
| 9 | 19.57 | 18.77 | 21.33 | 20.61 | 19.72 | 0.6537 | |
| 19.02 | 19.42 | 21.51 | 19.90 | 20.15 | |||
| 10 | 18.12 | 19.96 | 22.63 | 19.35 | 20.95 | 0.5816 | |
| 18.76 | 18.79 | 24.18 | 19.90 | 18.75 | |||
| 11 | 18.47 | 20.30 | 21.72 | 19.21 | 20.31 | 0.2669 | |
| 19.30 | 17.84 | 22.59 | 20.46 | 19.78 | |||
| 12 | 18.61 | 19.06 | 21.85 | 19.78 | 20.70 | 0.7691 | |
| 19.10 | 18.06 | 22.7 | 18.13 | 21.20 | |||
| 13 | 18.78 | 18.91 | 21.45 | 20.24 | 20.62 | 0.4743 | |
| 18.43 | 20.35 | 21.95 | 19.60 | 19.67 | |||
| 14 | 18.23 | 16.95 | 21.90 | 24.85 | 18.06 | 0.735 | |
| 18.80 | 18.80 | 22.22 | 21.31 | 18.89 |
a The correlation coefficient of human p53REs with 3 bp spacer and mouse p53REs with 8 bp spacer is R2 = 0.3968
Dataset of experimental verified p53 response elements
| Trarget gene and binding site | DNA sequence | Quarter-site coupling probability | Reference | ||||
|---|---|---|---|---|---|---|---|
| Cell cycle | Q1234 | T13 | T24 | H14 | H23 | ||
| 14-3-3 σ-site 2 | 0.13 | 0.13 | 0.21 | 0.45 | 0.08 | ( | |
| 14-3-3 σ -site 1 | 0.16 | 0.17 | 0.24 | 0.31 | 0.13 | ( | |
| B99 | 0.15 | 0.21 | 0.15 | 0.39 | 0.10 | ( | |
| Cyclin G | 0.15 | 0.15 | 0.21 | 0.37 | 0.12 | ( | |
| Cyclin G,C | 0.15 | 0.19 | 0.17 | 0.37 | 0.12 | ( | |
| BTG2 | 0.21 | 0.22 | 0.17 | 0.19 | 0.22 | ( | |
| gml | 0.16 | 0.17 | 0.24 | 0.30 | 0.13 | ( | |
| p21-5′ site | 0.18 | 0.21 | 0.25 | 0.20 | 0.17 | ( | |
| p21-3′ | 0.16 | 0.24 | 0.16 | 0.31 | 0.13 | ( | |
| CDKN1a | 0.18 | 0.21 | 0.25 | 0.20 | 0.17 | ( | |
| GDF | 0.16 | 0.13 | 0.27 | 0.28 | 0.16 | ( | |
| GDF | 0.16 | 0.21 | 0.23 | 0.24 | 0.16 | ( | |
| RB | 0.25 | 0.17 | 0.22 | 0.17 | 0.18 | ( | |
| CCNG1 | 0.16 | 0.20 | 0.25 | 0.24 | 0.15 | ( | |
| PCBB4 | 0.18 | 0.19 | 0.21 | 0.19 | 0.22 | ( | |
| Average | |||||||
| Standard deviation | |||||||
| Growth | |||||||
| TGFA | 0.16 | 0.18 | 0.16 | 0.34 | 0.15 | ( | |
| TGFA | 0.14 | 0.17 | 0.18 | 0.43 | 0.09 | ( | |
| Average | |||||||
| Death receptor | |||||||
| m-FAS | 0.14 | 0.20 | 0.17 | 0.38 | 0.11 | ( | |
| TNFRSF | 0.14 | 0.24 | 0.15 | 0.34 | 0.13 | ( | |
| PIDD | 0.19 | 0.17 | 0.24 | 0.20 | 0.20 | ( | |
| H-FAS,A | 0.14 | 0.19 | 0.18 | 0.36 | 0.12 | ( | |
| Average | |||||||
| Standard deviation | |||||||
| DNA repair | |||||||
| GADD45A | 0.18 | 0.22 | 0.20 | 0.25 | 0.15 | ( | |
| rrm2b (p53R2) | 0.16 | 0.16 | 0.22 | 0.33 | 0.14 | ( | |
| PCNA | 0.17 | 0.26 | 0.20 | 0.22 | 0.15 | ( | |
| Pcna | 0.17 | 0.18 | 0.30 | 0.21 | 0.15 | ( | |
| Average | |||||||
| Standard deviation | |||||||
| Apoptosis | |||||||
| Bax-A | 0.19 | 0.18 | 0.22 | 0.19 | 0.22 | ( | |
| BAX-B,A | 0.17 | 0.21 | 0.21 | 0.29 | 0.13 | ( | |
| BAX-mouse | 0.19 | 0.21 | 0.20 | 0.19 | 0.22 | ( | |
| BAX-human | 0.15 | 0.23 | 0.17 | 0.37 | 0.10 | ( | |
| IRDD | 0.14 | 0.21 | 0.17 | 0.39 | 0.09 | ( | |
| IRDD | 0.19 | 0.19 | 0.22 | 0.19 | 0.22 | ( | |
| ei24/PIG8 | 0.16 | 0.23 | 0.18 | 0.32 | 0.11 | ( | |
| IGFBP3 A,A | 0.19 | 0.19 | 0.22 | 0.23 | 0.18 | ( | |
| IGFBP3 B,A | 0.13 | 0.16 | 0.17 | 0.46 | 0.08 | ( | |
| MCG10, RE-1 | 0.18 | 0.19 | 0.21 | 0.19 | 0.22 | ( | |
| MCG10, RE-1 (PCBB4) | 0.18 | 0.24 | 0.17 | 0.21 | 0.20 | ( | |
| NOXA | 0.16 | 0.19 | 0.20 | 0.31 | 0.14 | ( | |
| p53aip1 | 0.17 | 0.18 | 0.27 | 0.22 | 0.17 | ( | |
| PERP, 218 | 0.18 | 0.19 | 0.23 | 0.17 | 0.23 | ( | |
| PERP, 2097 | 0.18 | 0.17 | 0.25 | 0.20 | 0.19 | ( | |
| TP5313 | 0.16 | 0.13 | 0.30 | 0.30 | 0.11 | ( | |
| bbc3 (puma-bs2) | 0.14 | 0.15 | 0.25 | 0.33 | 0.13 | ( | |
| PUMA-BS1 | 0.18 | 0.16 | 0.26 | 0.13 | 0.27 | ( | |
| pDINP1 | 0.17 | 0.26 | 0.18 | 0.26 | 0.13 | ( | |
| p2rx (P2XM) | 0.19 | 0.21 | 0.19 | 0.24 | 0.17 | ( | |
| Ctsd | 0.19 | 0.19 | 0.22 | 0.19 | 0.22 | ( | |
| cFOS,O | 0.16 | 0.19 | 0.20 | 0.31 | 0.34 | ( | |
| fas | 0.14 | 0.16 | 0.20 | 0.37 | 0.12 | ( | |
| Average | |||||||
| Standard deviation | |||||||
| Positive regulation | |||||||
| SCARA | 0.16 | 0.21 | 0.19 | 0.30 | 0.14 | ( | |
| mdm2 | 0.14 | 0.22 | 0.17 | 0.34 | 0.14 | ( | |
| MDM2-RE2 | 0.14 | 0.13 | 0.20 | 0.41 | 0.12 | ( | |
| mdm2 | 0.15 | 0.19 | 0.19 | 0.35 | 0.13 | ( | |
| mdr1b | 0.16 | 0.21 | 0.17 | 0.33 | 0.14 | ( | |
| PA26 | 0.16 | 0.19 | 0.22 | 0.29 | 0.14 | ( | |
| PA26,C | 0.16 | 0.19 | 0.22 | 0.27 | 0.16 | ( | |
| RGC,O | 0.14 | 0.16 | 0.21 | 0.39 | 0.11 | ( | |
| RGC | 0.18 | 0.15 | 0.28 | 0.19 | 0.20 | ( | |
| S100A2 | 0.16 | 0.26 | 0.16 | 0.30 | 0.13 | ( | |
| mmP2 | 0.15 | 0.16 | 0.18 | 0.39 | 0.12 | ( | |
| Average | |||||||
| Standard deviation | |||||||
| Negative regulation | |||||||
| Bdk | 0.17 | 0.21 | 0.23 | 0.22 | 0.17 | ( | |
| GPX | 0.13 | 0.16 | 0.18 | 0.43 | 0.10 | ( | |
| cFOS,O | 0.16 | 0.25 | 0.20 | 0.24 | 0.15 | ( | |
| Met | 0.19 | 0.26 | 0.10 | 0.29 | 0.16 | ( | |
| Cytokeratin 8 | 0.18 | 0.07 | 0.35 | 0.20 | 0.20 | ( | |
| Dickkopf-1 | 0.19 | 0.17 | 0.24 | 0.20 | 0.21 | ( | |
| EEf1A1 | 0.19 | 0.21 | 0.19 | 0.22 | 0.19 | ( | |
| EEf1A1 | 0.19 | 0.22 | 0.19 | 0.19 | 0.21 | ( | |
| EEf1A1 | 0.18 | 0.25 | 0.16 | 0.25 | 0.16 | EF-1 α E3 in ( | |
| EGFR | 0.31 | 0.22 | 0.14 | 0.19 | 0.15 | ( | |
| CX3 (Fractalkine) | 0.18 | 0.20 | 0.21 | 0.20 | 0.21 | ( | |
| HGF | 0.29 | 0.18 | 0.23 | 0.18 | 0.13 | ( | |
| HIC-1 | 0.19 | 0.20 | 0.20 | 0.18 | 0.24 | ( | |
| M-PGAM | 0.14 | 0.10 | 0.24 | 0.43 | 0.08 | ( | |
| MCK | 0.14 | 0.10 | 0.22 | 0.47 | 0.08 | ( | |
| SERPine1 | 0.17 | 0.17 | 0.24 | 0.27 | 0.16 | ( | |
| Sgk | 0.21 | 0.16 | 0.29 | 0.20 | 0.14 | ( | |
| sm α actin | 0.16 | 0.12 | 0.24 | 0.39 | 0.10 | ( | |
| TAP1 | 0.18 | 0.20 | 0.23 | 0.21 | 0.18 | ( | |
| THBs2 | 0.20 | 0.22 | 0.21 | 0.19 | 0.18 | ( | |
| THBs2 | 0.18 | 0.20 | 0.23 | 0.19 | 0.21 | ( | |
| TIMP-3 | 0.19 | 0.22 | 0.18 | 0.17 | 0.25 | ( | |
| SERPI (Maspin) | 0.189 | 0.184 | 0.222 | 0.224 | 0.181 | ( | |
| cds2 | 0.189 | 0.19 | 0.22 | 0.247 | 0.154 | ( | |
| Average | |||||||
| Standard deviation | |||||||
| Mitosis | |||||||
| PLK2 | 0.31 | 0.23 | 0.14 | 0.19 | 0.13 | ( | |
| PLK2 | 0.18 | 0.18 | 0.27 | 0.38 | 0.14 | ( | |
| PLK2 | 0.30 | 0.17 | 0.19 | 0.21 | 0.13 | ( | |
| Average | |||||||
| Human Repressor | |||||||
| TRPM | 0.19 | 0.16 | 0.27 | 0.19 | 0.19 | ( | |
| TRPM | 0.16 | 0.13 | 0.27 | 0.32 | 0.12 | ( | |
| TRPM | 0.19 | 0.19 | 0.23 | 0.24 | 0.16 | ( | |
| TRPM | 0.18 | 0.14 | 0.29 | 0.20 | 0.19 | ( | |
| ODC1 | 0.18 | 0.22 | 0.20 | 0.21 | 0.19 | ( | |
| ODC1 | 0.19 | 0.19 | 0.23 | 0.18 | 0.22 | ( | |
| CRYZ | 0.27 | 0.15 | 0.26 | 0.17 | 0.14 | ( | |
| slc38 | 0.18 | 0.18 | 0.24 | 0.20 | 0.19 | ( | |
| p22/PRG1 | 0.19 | 0.16 | 0.30 | 0.16 | 0.19 | ( | |
| ANLN | 0.17 | 0.21 | 0.21 | 0.22 | 0.19 | ( | |
| scd | 0.19 | 0.21 | 0.21 | 0.18 | 0.22 | ( | |
| Hspa8 | 0.18 | 0.14 | 0.28 | 0.22 | 0.18 | ( | |
| NOS3 | 0.28 | 0.16 | 0.25 | 0.17 | 0.15 | ( | |
| CDC25C | 0.18 | 0.23 | 0.19 | 0.18 | 0.22 | ( | |
| Average | |||||||
| Standard deviation | |||||||